As Soul13 pointed out in old thread (tks!) - I had made several...

As Soul13 pointed out in old thread (tks!) - I had made several errors in co-relating data since Mar2020. So I re-read everything for 2020....with
~16 cups of tea...

One key thing I found buried in the IPO docs (Page121 of the 139page)


So, AT1 does have a current licence agreement with Access Bio allowing them to build Pascal OEM device for their specific test use. Its a good precedence, methinks, and shows that AT1 will outsource manufacture to a trusted partner, which also reduces the single site manufacturing risks.

Potentially, Lumos FebriDX/ / AccessBio HCV might end up with similar arrangements (both use Pascal OEM platform) + both have lotsa cash to scaleup their sites as needed. It would certainly not limit their growth due to any AT1 capacity constraints...all AT1 has to do is keeping collecting revenue + monitoring their needs/manufacturing material supply...another Qtr should start to show the shape of these biz better.....